Hims & Hers Health (NYSE:HIMS) Trading Up 1.7% - Still a Buy?

Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) traded up 1.7% during mid-day trading on Wednesday . The stock traded as high as $56.27 and last traded at $56.21. 11,531,591 shares changed hands during mid-day trading, a decline of 63% from the average session volume of 31,441,092 shares. The stock had previously closed at $55.25.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the stock. UBS Group reaffirmed a "mixed" rating on shares of Hims & Hers Health in a report on Tuesday, May 6th. Wall Street Zen cut Hims & Hers Health from a "buy" rating to a "hold" rating in a research note on Saturday, June 7th. Needham & Company LLC lifted their target price on Hims & Hers Health from $61.00 to $65.00 and gave the stock a "buy" rating in a research note on Wednesday, June 4th. Leerink Partners upped their price objective on shares of Hims & Hers Health from $24.00 to $40.00 and gave the company a "market perform" rating in a report on Tuesday, February 25th. Finally, Canaccord Genuity Group upped their price objective on shares of Hims & Hers Health from $38.00 to $68.00 and gave the company a "buy" rating in a report on Wednesday, February 19th. Two research analysts have rated the stock with a sell rating, nine have given a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Hold" and a consensus price target of $38.00.

Hims & Hers Health Stock Down 3.2%

The business has a 50 day simple moving average of $45.09 and a 200 day simple moving average of $38.21. The company has a market capitalization of $12.38 billion, a PE ratio of 125.75 and a beta of 2.09.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last posted its earnings results on Monday, May 5th. The company reported $0.20 EPS for the quarter, topping the consensus estimate of $0.12 by $0.08. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The firm had revenue of $586.01 million for the quarter, compared to analyst estimates of $535.21 million. During the same period last year, the company earned $0.05 earnings per share. Hims & Hers Health's revenue for the quarter was up 110.7% compared to the same quarter last year. Equities analysts expect that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Insider Buying and Selling at Hims & Hers Health

In other Hims & Hers Health news, CEO Andrew Dudum sold 128,127 shares of the stock in a transaction on Monday, March 17th. The stock was sold at an average price of $33.98, for a total transaction of $4,353,755.46. Following the sale, the chief executive officer now owns 173,655 shares in the company, valued at approximately $5,900,796.90. This represents a 42.46% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, COO Melissa Baird sold 33,333 shares of the stock in a transaction on Monday, April 21st. The stock was sold at an average price of $25.78, for a total value of $859,324.74. Following the completion of the transaction, the chief operating officer now directly owns 805,083 shares in the company, valued at $20,755,039.74. This trade represents a 3.98% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 628,067 shares of company stock valued at $25,832,688 in the last ninety days. Insiders own 13.71% of the company's stock.

Institutional Investors Weigh In On Hims & Hers Health

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Blume Capital Management Inc. increased its holdings in shares of Hims & Hers Health by 100.0% in the fourth quarter. Blume Capital Management Inc. now owns 1,200 shares of the company's stock valued at $29,000 after buying an additional 600 shares in the last quarter. Geneos Wealth Management Inc. purchased a new position in Hims & Hers Health during the 1st quarter worth approximately $30,000. Smartleaf Asset Management LLC grew its position in Hims & Hers Health by 4,415.6% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,445 shares of the company's stock worth $36,000 after purchasing an additional 1,413 shares in the last quarter. Summit Securities Group LLC purchased a new position in Hims & Hers Health during the 4th quarter worth approximately $38,000. Finally, UMB Bank n.a. grew its position in Hims & Hers Health by 247.5% during the 1st quarter. UMB Bank n.a. now owns 1,310 shares of the company's stock worth $39,000 after purchasing an additional 933 shares in the last quarter. Institutional investors own 63.52% of the company's stock.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.